A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma
← catalyst calendarNCT07525375 · readout in 1,008 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
69estimated
Sites
39
Countries
Argentina, Czechia, Hungary +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-14 | actual | When the study began enrolling |
| Primary completion | 2029-05-23 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-05-23 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Asthma
Interventions
- Combination product: GP MDI
- Combination product: BFF MDI
- Combination product: Placebo MDI
Primary outcome
what the primary-completion date above is the date OFChange from baseline in Forced Expiratory volume in one second (FEV1) at 1-hour post-dose measured at End of treatment (EoT)
measured at 3 weeks
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed